159 related articles for article (PubMed ID: 30739130)
1. Toreforant, an orally active histamine H
Boyle DL; DePrimo SE; Calderon C; Chen D; Dunford PJ; Barchuk W; Firestein GS; Thurmond RL
Inflamm Res; 2019 Apr; 68(4):261-274. PubMed ID: 30739130
[TBL] [Abstract][Full Text] [Related]
2. Toreforant, A Histamine H4 Receptor Antagonist, in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy: Results of 2 Phase II Studies.
Thurmond RL; Greenspan A; Radziszewski W; Xu XL; Miao Y; Chen B; Ge T; Zhou B; Baker DG; Pavlova D; Ritchlin CT; Tanaka Y; Takeuchi T; Smolen JS
J Rheumatol; 2016 Sep; 43(9):1637-42. PubMed ID: 27422891
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Toreforant, a Selective Histamine H4 Receptor Antagonist, for the Treatment of Moderate-to-Severe Plaque Psoriasis: Results from a Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Trial.
Frankel E; Song M; Li S; Jiang J; Thurmond RL; Randazzo B
J Drugs Dermatol; 2018 Aug; 17(8):873-879. PubMed ID: 30124726
[TBL] [Abstract][Full Text] [Related]
4. The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis.
Boyle DL; Soma K; Hodge J; Kavanaugh A; Mandel D; Mease P; Shurmur R; Singhal AK; Wei N; Rosengren S; Kaplan I; Krishnaswami S; Luo Z; Bradley J; Firestein GS
Ann Rheum Dis; 2015 Jun; 74(6):1311-6. PubMed ID: 25398374
[TBL] [Abstract][Full Text] [Related]
5. A phase 2a study of toreforant, a histamine H
Kollmeier AP; Barnathan ES; O'Brien C; Chen B; Xia YK; Zhou B; Loza MJ; Silkoff PE; Ge M; Thurmond RL
Ann Allergy Asthma Immunol; 2018 Nov; 121(5):568-574. PubMed ID: 30102965
[TBL] [Abstract][Full Text] [Related]
6. Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY.
Boyapati A; Msihid J; Fiore S; van Adelsberg J; Graham NM; Hamilton JD
Arthritis Res Ther; 2016 Oct; 18(1):225. PubMed ID: 27716324
[TBL] [Abstract][Full Text] [Related]
7. [Adalimumab plus methotrexate for the treatment of rheumatoid arthritis: a multi-center randomized, double-blind, placebo-controlled clinical study.].
Huang F; Zhang FC; Bao CD; Tao Y; Gu JR; Xu JH; Zhu P; Xu HJ; Zhang ZY; Zhao DB; Wu DH
Zhonghua Nei Ke Za Zhi; 2009 Nov; 48(11):916-21. PubMed ID: 20079321
[TBL] [Abstract][Full Text] [Related]
8. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study.
Weisman MH; Moreland LW; Furst DE; Weinblatt ME; Keystone EC; Paulus HE; Teoh LS; Velagapudi RB; Noertersheuser PA; Granneman GR; Fischkoff SA; Chartash EK
Clin Ther; 2003 Jun; 25(6):1700-21. PubMed ID: 12860493
[TBL] [Abstract][Full Text] [Related]
9. Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium.
Ducreux J; Durez P; Galant C; Nzeusseu Toukap A; Van den Eynde B; Houssiau FA; Lauwerys BR
Arthritis Rheumatol; 2014 Jan; 66(1):15-23. PubMed ID: 24449571
[TBL] [Abstract][Full Text] [Related]
10. Atacicept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase II, randomized, placebo-controlled trial.
van Vollenhoven RF; Kinnman N; Vincent E; Wax S; Bathon J
Arthritis Rheum; 2011 Jul; 63(7):1782-92. PubMed ID: 21452294
[TBL] [Abstract][Full Text] [Related]
11. Dynamic T cell receptor clonotype changes in synovial tissue of patients with early rheumatoid arthritis: effects of treatment with cyclosporin A (Neoral).
VanderBorght A; De Keyser F; Geusens P; De Backer M; Malaise M; Baeten D; Van den Bosch F; Veys EM; Raus J; Stinissen P
J Rheumatol; 2002 Mar; 29(3):416-26. PubMed ID: 11908552
[TBL] [Abstract][Full Text] [Related]
12. Brief report: a phase IIa, randomized, double-blind, placebo-controlled trial of apilimod mesylate, an interleukin-12/interleukin-23 inhibitor, in patients with rheumatoid arthritis.
Krausz S; Boumans MJ; Gerlag DM; Lufkin J; van Kuijk AW; Bakker A; de Boer M; Lodde BM; Reedquist KA; Jacobson EW; O'Meara M; Tak PP
Arthritis Rheum; 2012 Jun; 64(6):1750-5. PubMed ID: 22170479
[TBL] [Abstract][Full Text] [Related]
13. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone.
Kremer JM; Cohen S; Wilkinson BE; Connell CA; French JL; Gomez-Reino J; Gruben D; Kanik KS; Krishnaswami S; Pascual-Ramos V; Wallenstein G; Zwillich SH
Arthritis Rheum; 2012 Apr; 64(4):970-81. PubMed ID: 22006202
[TBL] [Abstract][Full Text] [Related]
14. ABT-122, a Bispecific Dual Variable Domain Immunoglobulin Targeting Tumor Necrosis Factor and Interleukin-17A, in Patients With Rheumatoid Arthritis With an Inadequate Response to Methotrexate: A Randomized, Double-Blind Study.
Genovese MC; Weinblatt ME; Aelion JA; Mansikka HT; Peloso PM; Chen K; Li Y; Othman AA; Khatri A; Khan NS; Padley RJ
Arthritis Rheumatol; 2018 Nov; 70(11):1710-1720. PubMed ID: 29855172
[TBL] [Abstract][Full Text] [Related]
15. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial.
Kremer J; Li ZG; Hall S; Fleischmann R; Genovese M; Martin-Mola E; Isaacs JD; Gruben D; Wallenstein G; Krishnaswami S; Zwillich SH; Koncz T; Riese R; Bradley J
Ann Intern Med; 2013 Aug; 159(4):253-61. PubMed ID: 24026258
[TBL] [Abstract][Full Text] [Related]
16. Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers.
Kraan MC; Reece RJ; Barg EC; Smeets TJ; Farnell J; Rosenburg R; Veale DJ; Breedveld FC; Emery P; Tak PP
Arthritis Rheum; 2000 Aug; 43(8):1820-30. PubMed ID: 10943872
[TBL] [Abstract][Full Text] [Related]
17. Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial.
Smolen JS; Nash P; Durez P; Hall S; Ilivanova E; Irazoque-Palazuelos F; Miranda P; Park MC; Pavelka K; Pedersen R; Szumski A; Hammond C; Koenig AS; Vlahos B
Lancet; 2013 Mar; 381(9870):918-29. PubMed ID: 23332236
[TBL] [Abstract][Full Text] [Related]
18. A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis.
van Holten J; Pavelka K; Vencovsky J; Stahl H; Rozman B; Genovese M; Kivitz AJ; Alvaro J; Nuki G; Furst DE; Herrero-Beaumont G; McInnes IB; Musikic P; Tak PP
Ann Rheum Dis; 2005 Jan; 64(1):64-9. PubMed ID: 15242865
[TBL] [Abstract][Full Text] [Related]
19. Safety, tolerability, pharmacokinetics, and pharmacodynamics of anti-TWEAK monoclonal antibody in patients with rheumatoid arthritis.
Wisniacki N; Amaravadi L; Galluppi GR; Zheng TS; Zhang R; Kong J; Burkly LC
Clin Ther; 2013 Aug; 35(8):1137-49. PubMed ID: 23928094
[TBL] [Abstract][Full Text] [Related]
20. E-selectin, interleukin 18, serum amyloid a, and matrix metalloproteinase 9 are associated with clinical response to golimumab plus methotrexate in patients with active rheumatoid arthritis despite methotrexate therapy.
Visvanathan S; Wagner C; Rojas J; Kay J; Dasgupta B; Matteson EL; Mack M; Baker DG; Rahman MU
J Rheumatol; 2009 Jul; 36(7):1371-9. PubMed ID: 19487269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
